COPD
The Pharmacy Times® Chronic Obstructive Pulmonary Disease (COPD) resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.
What can we help you find?
According to the survey results, 56% of patients with chronic obstructive pulmonary disease reported that COVID-19 has made it difficult for them to receive treatment
In the midst of the COVID-19 pandemic, it is important that individuals who are at higher risk for poor outcomes from infection with vaccine-preventable diseases remain up-to-date with their immunizations.
Pharmacists should familiarize themselves with these therapies to help patients lessen the risk of emergency department visits and hospitalizations.
In the study, more patients with allergies had chronic obstructive pulmonary disease (COPD), which is a known risk factor for severe disease with COVID-19.
They can help patients improve inhalation technique, ensuring better medication adherence.
Digital health tools were a major theme during the first-ever NASP Challenge, comprising 4 of the 5 finalists.
The triple combination therapy is the first single inhaler triple therapy approved for both asthma and COPD and is the only single inhaler triple therapy available as a once-daily inhalation.
Chronic obstructive pulmonary disease may remain undetected due to individuals thinking that the symptoms are a normal sign of aging.
Budesonide/glycopyrrolate/formoterol fumarate (Breztri Aerosphere, AstraZeneca) has been approved by the FDA for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD), according to a press release.
Although COPD often develops as a result of smoking, researchers have long puzzled over why nearly one-third of cases occur in people who never smoked.
At the first educational session of PQA, the speakers discussed pharmacists’ roles in influencing outcomes associated with social determinants of health in the US population.
During this period, 1834 participants developed lung cancer, of whom 290 had COPD and 1544 did not, according to the researchers.